FiercePharma, by Arlene Weintraub, Jan 29, 2019 When Dave Lennon, president of Novartis unit AveXis, said in November that the company’s experimental gene therapy to treat spinal muscular atrophy (SMA) could be cost-effective at a price of $4 million to $5 million, some pricing critics immediately raised red flags. But then the Institute for Clinical […]
19. April 2018 Interview with Anke Holtorf, Managing Director, Health Outcomes Strategies, GmbH on the subject of patient involvement in pharmaceutical market access. Patients are playing an increasingly powerful part in market access, and this was recently explored within a chapter in the newly-published book Pharmaceutical Market Access in Developed Countries. For full text see http://patientfocusedmedicine.org/integrating-patient-insights-challenges-and-opportunities/
FiercePharma / by Eric Sagonowsky onMay 3, 2017 On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim. Through the first-of-its-kind contract, if a patient on Repatha has a heart attack or stroke, the drugmaker will provide a full refund. As the […]
There is a lot of talk in industry, among the public, or among payers about VALUE related to health services or products. But do they mean the same, when they talk about it. Read a recent (March 2015) assay by Ed Schoonveld in ‘PharmExec.com’ : http://www.pharmexec.com/can-payers-and-drug-industry-agree-real-value?
Fierce Pharma, February 19, 2015 | By Eric Palmer Drugmakers are often at odds with the National Institute for Health and Care Excellence (NICE) in England, saying it is stingy in what it will approve as payments for their best new treatments. But the industry and the gatekeeper have pulled together in defending against a […]
FiercePharma, December 11, 2013 | By Tracy Staton Gilead Sciences ($GILD) can take the sort of pricing protest that greeted its breakthrough hepatitis C treatment Sovaldi this week–the kind from access-to-medicine advocates. But when payers balk, that’s a different story. A horror story, even, that could frighten drugmakers long accustomed to pricing freedom in the […]
FiercePharma, December 16, 2013 | By Tracy Staton More new drugs. More drug sales? Not so much. As The Wall Street Journal reports, pharma companies racked up 271 new drug approvals from 2006 to 2010, but only a baker’s dozen of them have broken through the blockbuster barrier. That’s a major comedown from the previous […]
Pharmatimes Online. 15 May 2013 The pharmaceutical industry has now entered the Outcomes Era where compounds must supply convincing evidence of a new drug’s value, with proof of the best possible health outcomes and additional benefits if it is to achieve attractive price and reimbursement levels, says new research.As many as 60% of pharmaceutical executives […]